Hormonal
Increased expression of Monocyte Chemoattractant Protein-1 (MCP-1) in adipose tissue directly causes macrophage infiltration, insulin resistance, and hepatic steatosis in obesity.
This research identifies MCP-1 as a key link between fat tissue and insulin resistance. While this is a mouse study, it suggests that therapies targeting MCP-1 or its receptor (CCR2) could potentially treat insulin resistance and fatty liver in obese humans by reducing fat tissue inflammation.
These findings suggest that an increase in MCP-1 expression in adipose tissue contributes to the macrophage infiltration into this tissue, insulin resistance, and hepatic steatosis associated with obesity in mice.
Why this rating
High-quality mechanistic evidence using multiple mouse models (transgenic overexpression, knockout, and dominant-negative inhibition) with consistent results.
Source
MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity
Hiroyuki Kanda · Journal of Clinical Investigation · 2006
DOI 10.1172/jci26498
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →